News | Cath Lab | August 14, 2015

IMRIS Inc. Assets Acquired by Deerfield Management Company

Company reaches agreement with Deerfield Management Company L.P. to purchase imaging and service businesses and robotics intellectual property

IMRIS, going concern sale, Deerfield Management Company L.P., imaging and service, robotics intellectual property

August 14, 2015 — IMRIS Inc. announced in late July that investment funds managed by Deerfield Management Company L.P. (“Deerfield”) were the prevailing parties in the recently completed sale process for the company’s assets. Deerfield is a healthcare-focused investment firm that manages over $6 billion in assets, and has been the company’s lender, both prior to and following the commencement of the company’s chapter 11 proceedings.

Jay D. Miller, IMRIS president and CEO, noted that Deerfield’s emergence as the prevailing bidder came as the result of a comprehensive sales process that included a large number of both strategic and financial parties.

According to Miller, the acquisition includes IMRIS’s imaging and service operating businesses in China, Germany and Japan, as well as the robotics intellectual property.

A hearing to approve the sale to Deerfield was scheduled before the United States Bankruptcy Court for the District of Delaware on August 12, with the transaction anticipated to close shortly thereafter.

For more information:

Related Content

Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init